Athersys (ATHX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends ATHX vs. LIXT, NBY, MTNB, SBFM, ARAV, PTPI, VINC, ZVSA, SHPH, and ATXIShould you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Lixte Biotechnology (LIXT), NovaBay Pharmaceuticals (NBY), Matinas Biopharma (MTNB), Sunshine Biopharma (SBFM), Aravive (ARAV), Petros Pharmaceuticals (PTPI), Vincerx Pharma (VINC), ZyVersa Therapeutics (ZVSA), Shuttle Pharmaceuticals (SHPH), and Avenue Therapeutics (ATXI). These companies are all part of the "pharmaceutical preparations" industry. Athersys vs. Lixte Biotechnology NovaBay Pharmaceuticals Matinas Biopharma Sunshine Biopharma Aravive Petros Pharmaceuticals Vincerx Pharma ZyVersa Therapeutics Shuttle Pharmaceuticals Avenue Therapeutics Athersys (NASDAQ:ATHX) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation. Is ATHX or LIXT more profitable? Athersys' return on equity of 0.00% beat Lixte Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets AthersysN/A N/A -223.03% Lixte Biotechnology N/A -5,562.77%-130.48% Does the MarketBeat Community favor ATHX or LIXT? Athersys received 365 more outperform votes than Lixte Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformAthersysOutperform Votes36557.12% Underperform Votes27442.88% Lixte BiotechnologyN/AN/A Which has higher earnings & valuation, ATHX or LIXT? Lixte Biotechnology has lower revenue, but higher earnings than Athersys. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthersys$146K0.00-$72.53M-$2.03N/ALixte BiotechnologyN/AN/A-$5.09M-$1.73-0.73 Do insiders & institutionals hold more shares of ATHX or LIXT? 19.4% of Athersys shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 14.8% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer ATHX or LIXT? In the previous week, Athersys had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 1 mentions for Athersys and 0 mentions for Lixte Biotechnology. Athersys' average media sentiment score of 0.00 equaled Lixte Biotechnology'saverage media sentiment score. Company Overall Sentiment Athersys Neutral Lixte Biotechnology Neutral Which has more risk & volatility, ATHX or LIXT? Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. SummaryAthersys beats Lixte Biotechnology on 6 of the 11 factors compared between the two stocks. Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHX vs. The Competition Export to ExcelMetricAthersysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$833,000.00$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.015.8226.1519.13Price / SalesN/A268.05435.3370.72Price / CashN/A65.6738.0134.83Price / BookN/A6.717.644.62Net Income-$72.53M$138.55M$3.19B$245.94M Athersys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHXAthersysN/AN/AN/AN/A$833,000.00$146,000.00-0.0124Analyst ForecastLIXTLixte BiotechnologyN/A$1.45+3.6%N/A-45.3%$3.26MN/A-0.844Gap UpHigh Trading VolumeNBYNovaBay Pharmaceuticals1.624 of 5 stars$0.66-1.3%$0.85+28.6%-87.8%$3.23M$14.73M-0.0130Analyst ForecastGap DownMTNBMatinas BiopharmaN/A$0.61+1.6%N/AN/A$3.10M$1.10M-0.1330Gap UpSBFMSunshine Biopharma1.75 of 5 stars$2.51+0.8%$15.00+497.6%-59.9%$3.07M$32.96M-0.023ARAVAraviveN/A$0.04flatN/AN/A$2.95M$9.14M0.0020High Trading VolumePTPIPetros Pharmaceuticals0.6222 of 5 stars$0.29+18.4%N/A-92.1%$2.94M$5.82M-0.0620Gap DownHigh Trading VolumeVINCVincerx Pharma2.2393 of 5 stars$1.30+1.6%$40.00+2,976.9%-98.0%$2.91MN/A-0.0660ZVSAZyVersa Therapeutics2.4631 of 5 stars$1.24-4.6%$120.00+9,577.4%-80.0%$2.90MN/A0.002SHPHShuttle PharmaceuticalsN/A$0.70+1.3%N/AN/A$2.85MN/A-0.175Gap UpATXIAvenue Therapeutics1.2891 of 5 stars$1.36flatN/A-87.9%$2.79MN/A0.074Negative News Related Companies and Tools Related Companies Lixte Biotechnology Competitors NovaBay Pharmaceuticals Competitors Matinas Biopharma Competitors Sunshine Biopharma Competitors Aravive Competitors Petros Pharmaceuticals Competitors Vincerx Pharma Competitors ZyVersa Therapeutics Competitors Shuttle Pharmaceuticals Competitors Avenue Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATHX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
